C² Pharma Opens Access to Digoxin API as Potential COVID-19 Treatment

Luxembourg-based API maker C² Pharma announced that it is making its safety stock of Digoxin available for governments and researchers as a possible COVID-19 treatment.

The API was identified for its potential to reduce COVID-19 symptoms in patients in combination with other antiviral drugs based on research from South Korea and India.

The company is offering samples of Digoxin API free of charge to researchers and clinicians working on COVID-19 efficacy trials.